StockData
Cytek Biosciences, Inc. logo

Cytek Biosciences, Inc. (CTKB) stock

CTKBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/309% below fair value
$5.92+0.22 (+3.86%)

Close on Nov 18, 2026Market cap $769.50MP/E –Yield –

Cytek Biosciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Cytek Biosciences's operating income for the twelve months ending Jun 30, 2026 was -$44.65M. For fiscal 2025 it was -$40.38M. The highest annual figure on record is $13.66M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$40.38M–
FY2024Dec 31, 2024-$20.52M–
FY2023Dec 31, 2023-$27.85M–
FY2022Dec 31, 2022-$1.80M-119.7%
FY2021Dec 31, 2021$9.16M-33.0%
FY2020Dec 31, 2020$13.66M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$11.40M–
Q1 FY2026Mar 31, 2026-$18.46M–
Q4 FY2025Dec 31, 2025-$5.59M-287.3%
Q3 FY2025Sep 30, 2025-$9.19M–
Q2 FY2025Jun 30, 2025-$10.62M–
Q1 FY2025Mar 31, 2025-$14.98M–
Q4 FY2024Dec 31, 2024$2.99M–
Q3 FY2024Sep 30, 2024-$4.25M–
Q2 FY2024Jun 30, 2024-$8.53M–
Q1 FY2024Mar 31, 2024-$10.73M–
Q4 FY2023Dec 31, 2023-$137.00K-263.1%
Q3 FY2023Sep 30, 2023-$6.42M-572.1%
Q2 FY2023Jun 30, 2023-$9.13M–
Q1 FY2023Mar 31, 2023-$12.16M–
Q4 FY2022Dec 31, 2022$84.00K-93.6%
Q3 FY2022Sep 30, 2022$1.36M-53.1%
Q2 FY2022Jun 30, 2022-$891.00K-123.4%
Q1 FY2022Mar 31, 2022-$2.36M-308.2%
Q4 FY2021Dec 31, 2021$1.32M-83.3%
Q3 FY2021Sep 30, 2021$2.90M-56.8%
Q2 FY2021Jun 30, 2021$3.81M–
Q1 FY2021Mar 31, 2021$1.13M–
Q4 FY2020Dec 31, 2020$7.88M–
Q3 FY2020Sep 30, 2020$6.71M–
Q2 FY2020Jun 30, 2020-$218.00K–

More Cytek Biosciences figures

See a number that looks wrong?